Meredith Manning - 28 Oct 2026 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
29 Oct 2026, 16:30:02 UTC
Prior SEC filing
01 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Meredith Manning
Filing notes and source

Key filing fact

Meredith Manning filed Form 4 for Unicycive Therapeutics, Inc. (UNCY) on 29 Oct 2026.

Key facts

  • This page summarizes Meredith Manning's Form 4 filing for Unicycive Therapeutics, Inc. (UNCY).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 29 Oct 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 01 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001752631 Primary reporting owner

Manning Meredith

Relationship
Director
Address
C/O UNICYCIVE THERAPEUTICS, INC., 1975 W. EL CAMINO REAL SUITE 204, MOUNTAIN VIEW
Signature
/s/ Meredith Manning
Signature date
29 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UNCY transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+3,350
Change %
Price
$0.000000*
Shares after
3,350
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,350
Exercise price
$0.000000
Footnotes
F1
UNCY transaction Derivative

Stock Options

Award

Transaction value
Shares
+27,000
Change %
Price
$0.000000*
Shares after
27,000
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
27,000
Exercise price
$3.76
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents grant of restricted stock units payable solely in common stock of the Issuer. 837 shares vest upon grant and 209 vest monthly over 12 months beginning Nov. 1, 2026, subject to the Reporting Person's continued service with the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .